NCT07868926RecruitingPhase 1
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- 16 Oct 2026
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Diseases
- Polycystic kidney disease
- NCT number
- NCT07868926
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 8
- From 16 Oct 2026 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Exposure to any nonenvironmental radiation (e.g., diagnostic medical imaging or occupational exposure) within 12 months before study drug administration
- Participation in more than 1 radiolabeled study (if the previous study's radiation exposure is unknown) or participation in more than 3 radiolabeled studies (if the previous studies' radiation exposure is known) in the 12 months before dosing or if the annual whole-body radiation exposure from all previous studies (including this dosing) is more than the FDA-allowed maximum whole body radiation exposure of 5000 mrem
- Other protocol defined Inclusion/Exclusion criteria will apply.
Other illness
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
Who the study is looking for
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
- A total body weight of more than (\>) 50 kg
- Participants must have regular bowel movements (i.e., average of more than or equal to (\>=) 1 and less than or equal to (\<=)3 stools per day)
Age in the registry: 19 years to 55 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Celerion, Lincoln Coordinator of this site? Confirm its status | Lincoln | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.